.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Sarvodaya Healthcare recently completed a strategic Sarvodaya Healthcare hospital acquisition by taking over Nayati Hospital in Mathura. This move follows the successful approval from the National Company Law Tribunal (NCLT) through the Insolvency and Bankruptcy Code process. Consequently, the group's total bed capacity has surged from 800 to 1,200 units. Furthermore, this expansion aims to provide advanced tertiary medical services to patients across western Uttar Pradesh.
The Mathura facility has a standalone capacity of 400 beds. Currently, the group expects the hospital to be fully operational by June 2026. Additionally, the management plans to introduce various super-specialty departments. For instance, the hospital will focus on cardiology, oncology, and neurosciences. Moreover, they intend to pursue prestigious quality accreditations like NABH and NABL to ensure world-class care standards.
The acquired facility features robust infrastructure designed for complex medical interventions. It includes 100 ICU beds and nine modular operation theatres. Furthermore, the hospital provides 24x7 emergency and trauma care alongside advanced diagnostic services. As a result of this acquisition, Sarvodaya Healthcare now manages a workforce of over 5,500 healthcare professionals. They are also planning significant investments in technology upgrades and clinical recruitment.
Group Chairman Rakesh Gupta noted that this development reflects a commitment to expanding access to affordable healthcare. Therefore, the group continues to build its footprint beyond the Delhi-NCR region into emerging urban centres. This strategy will likely strengthen the regional healthcare ecosystem significantly.
Q1: What is the new total bed capacity of the Sarvodaya Healthcare group?
Following the acquisition of the 400-bed Mathura facility, the group's total capacity has increased to 1,200 beds.
Q2: When will the newly acquired hospital in Mathura become operational?
The group expects the hospital to be fully operational by June 2026 after necessary infrastructure upgrades.
Q3: Which medical specialties will the Mathura facility focus on?
The hospital will provide super-specialty services in cardiology, oncology, orthopaedics, neurosciences, gastroenterology, and critical care.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Sarvodaya Healthcare has acquired Nayati Hospital in Mathura through the NCLT process, increasing its total group bed capacity to 1,200 across North India....
7 months ago
As monsoon seasons elevate arboviral disease threats, Tamil Nadu has initiated an ICMR-monitored evaluation of the tetravalent dengue vaccine in Tenkasi district. Clinicians emphasize clinical monitoring, public prevention, and high-quality early pediatric care to reduce disease morbidity across endemic regions.
Today
A comparative cohort study evaluates vNOTES vs TLH hysterectomy for benign conditions, demonstrating shorter operative duration, faster return to daily activities, and equivalent female sexual function scores without increased dyspareunia.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
